The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Duchenne Muscular Dystrophy Therapeutics-Global Market Insights and Sales Trends 2024
Synopsis
Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.
The global Duchenne Muscular Dystrophy Therapeutics market size is expected to reach US$ 5209.6 million by 2029, growing at a CAGR of 21.1% from 2023 to 2029. The market is mainly driven by the significant applications of Duchenne Muscular Dystrophy Therapeutics in various end use industries. The expanding demands from the Hospitals, Clinics and Home Care,, are propelling Duchenne Muscular Dystrophy Therapeutics market. Pain Management Drugs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Corticosteroids segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Duchenne Muscular Dystrophy Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Duchenne Muscular Dystrophy Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Duchenne Muscular Dystrophy Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Duchenne Muscular Dystrophy Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Duchenne Muscular Dystrophy Therapeutics covered in this report include Bristol-Myers Squibb, FibroGen (US), Italfarmaco (Italy), Marathon, NS Pharma (US), PTC Therapeutics (US), Pfizer, ReveraGen BioPharma (US) and Santhera Pharmaceuticals (Switzerland), etc.
The global Duchenne Muscular Dystrophy Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bristol-Myers Squibb
FibroGen (US)
Italfarmaco (Italy)
Marathon
NS Pharma (US)
PTC Therapeutics (US)
Pfizer
ReveraGen BioPharma (US)
Santhera Pharmaceuticals (Switzerland)
Sarepta Therapeutics (US)
Global Duchenne Muscular Dystrophy Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Duchenne Muscular Dystrophy Therapeutics market, Segment by Type:
Pain Management Drugs
Corticosteroids
Prednisolone
Prednisone
Deflazacort
Global Duchenne Muscular Dystrophy Therapeutics market, by Application
Hospitals
Clinics
Home Care
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Duchenne Muscular Dystrophy Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.
The global Duchenne Muscular Dystrophy Therapeutics market size is expected to reach US$ 5209.6 million by 2029, growing at a CAGR of 21.1% from 2023 to 2029. The market is mainly driven by the significant applications of Duchenne Muscular Dystrophy Therapeutics in various end use industries. The expanding demands from the Hospitals, Clinics and Home Care,, are propelling Duchenne Muscular Dystrophy Therapeutics market. Pain Management Drugs, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Corticosteroids segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Duchenne Muscular Dystrophy Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Duchenne Muscular Dystrophy Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Duchenne Muscular Dystrophy Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Duchenne Muscular Dystrophy Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Duchenne Muscular Dystrophy Therapeutics covered in this report include Bristol-Myers Squibb, FibroGen (US), Italfarmaco (Italy), Marathon, NS Pharma (US), PTC Therapeutics (US), Pfizer, ReveraGen BioPharma (US) and Santhera Pharmaceuticals (Switzerland), etc.
The global Duchenne Muscular Dystrophy Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bristol-Myers Squibb
FibroGen (US)
Italfarmaco (Italy)
Marathon
NS Pharma (US)
PTC Therapeutics (US)
Pfizer
ReveraGen BioPharma (US)
Santhera Pharmaceuticals (Switzerland)
Sarepta Therapeutics (US)
Global Duchenne Muscular Dystrophy Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Duchenne Muscular Dystrophy Therapeutics market, Segment by Type:
Pain Management Drugs
Corticosteroids
Prednisolone
Prednisone
Deflazacort
Global Duchenne Muscular Dystrophy Therapeutics market, by Application
Hospitals
Clinics
Home Care
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Duchenne Muscular Dystrophy Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Duchenne Muscular Dystrophy Therapeutics
1.1 Duchenne Muscular Dystrophy Therapeutics Market Overview
1.1.1 Duchenne Muscular Dystrophy Therapeutics Product Scope
1.1.2 Duchenne Muscular Dystrophy Therapeutics Market Status and Outlook
1.2 Global Duchenne Muscular Dystrophy Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Duchenne Muscular Dystrophy Therapeutics Market Size by Region (2018-2029)
1.4 Global Duchenne Muscular Dystrophy Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Duchenne Muscular Dystrophy Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Duchenne Muscular Dystrophy Therapeutics Market Size (2018-2029)
1.6.1 North America Duchenne Muscular Dystrophy Therapeutics Market Size (2018-2029)
1.6.2 Europe Duchenne Muscular Dystrophy Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size (2018-2029)
1.6.4 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size (2018-2029)
2 Duchenne Muscular Dystrophy Therapeutics Market by Type
2.1 Introduction
2.1.1 Pain Management Drugs
2.1.2 Corticosteroids
2.1.3 Prednisolone
2.1.4 Prednisone
2.1.5 Deflazacort
2.2 Global Duchenne Muscular Dystrophy Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Duchenne Muscular Dystrophy Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Duchenne Muscular Dystrophy Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Duchenne Muscular Dystrophy Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Duchenne Muscular Dystrophy Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Duchenne Muscular Dystrophy Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Revenue Breakdown by Type (2018-2029)
3 Duchenne Muscular Dystrophy Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Home Care
3.2 Global Duchenne Muscular Dystrophy Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Duchenne Muscular Dystrophy Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Duchenne Muscular Dystrophy Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Duchenne Muscular Dystrophy Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Duchenne Muscular Dystrophy Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Duchenne Muscular Dystrophy Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Revenue Breakdown by Application (2018-2029)
4 Duchenne Muscular Dystrophy Therapeutics Competition Analysis by Players
4.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy Therapeutics as of 2022)
4.3 Date of Key Players Enter into Duchenne Muscular Dystrophy Therapeutics Market
4.4 Global Top Players Duchenne Muscular Dystrophy Therapeutics Headquarters and Area Served
4.5 Key Players Duchenne Muscular Dystrophy Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Duchenne Muscular Dystrophy Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Bristol-Myers Squibb
5.1.1 Bristol-Myers Squibb Profile
5.1.2 Bristol-Myers Squibb Main Business
5.1.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Products, Services and Solutions
5.1.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 Bristol-Myers Squibb Recent Developments
5.2 FibroGen (US)
5.2.1 FibroGen (US) Profile
5.2.2 FibroGen (US) Main Business
5.2.3 FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Products, Services and Solutions
5.2.4 FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 FibroGen (US) Recent Developments
5.3 Italfarmaco (Italy)
5.3.1 Italfarmaco (Italy) Profile
5.3.2 Italfarmaco (Italy) Main Business
5.3.3 Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Products, Services and Solutions
5.3.4 Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 Marathon Recent Developments
5.4 Marathon
5.4.1 Marathon Profile
5.4.2 Marathon Main Business
5.4.3 Marathon Duchenne Muscular Dystrophy Therapeutics Products, Services and Solutions
5.4.4 Marathon Duchenne Muscular Dystrophy Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 Marathon Recent Developments
5.5 NS Pharma (US)
5.5.1 NS Pharma (US) Profile
5.5.2 NS Pharma (US) Main Business
5.5.3 NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Products, Services and Solutions
5.5.4 NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 NS Pharma (US) Recent Developments
5.6 PTC Therapeutics (US)
5.6.1 PTC Therapeutics (US) Profile
5.6.2 PTC Therapeutics (US) Main Business
5.6.3 PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Products, Services and Solutions
5.6.4 PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 PTC Therapeutics (US) Recent Developments
5.7 Pfizer
5.7.1 Pfizer Profile
5.7.2 Pfizer Main Business
5.7.3 Pfizer Duchenne Muscular Dystrophy Therapeutics Products, Services and Solutions
5.7.4 Pfizer Duchenne Muscular Dystrophy Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 Pfizer Recent Developments
5.8 ReveraGen BioPharma (US)
5.8.1 ReveraGen BioPharma (US) Profile
5.8.2 ReveraGen BioPharma (US) Main Business
5.8.3 ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Products, Services and Solutions
5.8.4 ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 ReveraGen BioPharma (US) Recent Developments
5.9 Santhera Pharmaceuticals (Switzerland)
5.9.1 Santhera Pharmaceuticals (Switzerland) Profile
5.9.2 Santhera Pharmaceuticals (Switzerland) Main Business
5.9.3 Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Products, Services and Solutions
5.9.4 Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Revenue (US$ Million) & (2018-2023)
5.9.5 Santhera Pharmaceuticals (Switzerland) Recent Developments
5.10 Sarepta Therapeutics (US)
5.10.1 Sarepta Therapeutics (US) Profile
5.10.2 Sarepta Therapeutics (US) Main Business
5.10.3 Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Products, Services and Solutions
5.10.4 Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue (US$ Million) & (2018-2023)
5.10.5 Sarepta Therapeutics (US) Recent Developments
6 North America
6.1 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Duchenne Muscular Dystrophy Therapeutics Market Dynamics
11.1 Duchenne Muscular Dystrophy Therapeutics Industry Trends
11.2 Duchenne Muscular Dystrophy Therapeutics Market Drivers
11.3 Duchenne Muscular Dystrophy Therapeutics Market Challenges
11.4 Duchenne Muscular Dystrophy Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
